ArticleEBioMedicine2015
Ocular pseudoexfoliation syndrome and life span.
Article in EBioMedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Aqueous humor metabolomic profiling identifies a distinct signature in pseudoexfoliation syndrome.Frontiers in molecular biosciences · 2024Article
- 3D Modeling of the Crystalline Lens Complex under Pseudoexfoliation.Bioengineering (Basel, Switzerland) · 2022Article
- Exfoliation syndrome: association with systemic diseases-the Maccabi glaucoma study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Article
- Significant lifespan difference between primary open-angle glaucoma and pseudoexfoliation glaucoma.Heliyon · 2021Article
- Summary of Utah Project on Exfoliation Syndrome (UPEXS): using a large database to identify systemic comorbidities.BMJ open ophthalmology · 2021Review
- Clinical Features of Pseudoexfoliative Glaucoma in Treated Polish Patients.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Pseudoexfoliation syndrome: analysis of systemic comorbidities of 325 PEX-positive patients compared with 911 PEX-negative patients.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- Article
- Ocular Pseudoexfoliation Syndrome and Life Span: Act 2.EBioMedicine · 2015Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare life span of persons with and without ocular pseudoexfoliation syndrome (PES).
methodsThe study is based on an epidemiological survey conducted in Sør-Trøndelag county, Norway, in 1985-86. All inhabitants over 64 years of age (2109 individuals) were invited. Mortality information was obtained from The Norwegian Institute of Public Health in 2014, by which time 99% of the participants were deceased.
resultsWhen adjusting for age and gender, life span was not statistically different in persons with and without PES. Following the diagnosis of PES, patients' survival was up to, and beyond, 30 years.
conclusionsOur observations suggest that, despite all the systemic aberrations reported in persons with ocular PES, none or only marginal functional changes are caused in extraocular organs and tissues. The present study supports the notion that systemic PES is not a life-threatening condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.